Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Concord Healthcare Group Co., Ltd. Class H ( (HK:2453) ) has shared an announcement.
Concord Healthcare Group has announced a leadership reshuffle, with president Fu Xiao stepping down from the role effective 12 January 2026 as part of normal succession planning, while remaining an executive director and becoming an adviser to the company. The board has appointed Jiang Wei, previously head of the Group’s core AI business and a key figure in advancing its AI-driven oncology diagnosis and treatment capabilities, as the new president, tasking him with integrating the Group’s medical, data and AI strengths, focusing on its core oncology care operations, and accelerating international expansion to consolidate its leading position in AI-enabled cancer care.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
More about Concord Healthcare Group Co., Ltd. Class H
Concord Healthcare Group Co., Ltd. is a China-based medical services group focused on oncology care, integrating diagnostic and treatment capabilities with data resources and artificial intelligence technologies. Through entities such as Beijing Healthingkon Technology and several specialist cancer centers, the Group is building an AI-enabled oncology diagnosis and treatment platform and is pursuing both domestic development and overseas expansion to strengthen its position in the cancer-care industry.
Average Trading Volume: 476,029
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.51B
For detailed information about 2453 stock, go to TipRanks’ Stock Analysis page.